Revolution Medicines outlines $1.6B-$1.7B 2026 operating expenses as RAS(ON) inhibitor trials expand
Source: SeekingAlpha
2026-02-25 21:18:32 ET
More on Revolution Medicines
- Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript
- Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
- Merck Chooses Evolution Over Revolution - At Proposed Price, I'm Not Surprised
- Revolution Medicines reports Q4 results
- Revolution Medicines Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Revolution Medicines outlines $1.6B–$1.7B 2026 operating expenses as RAS(ON) inhibitor trials expand
Revolution Medicines Inc. Warrant
NASDAQ: RVMDW
RVMDW Trading
-5.71% G/L:
$1.65 Last:
8,341 Volume:
$1.64 Open:
RVMDW Latest News
RVMDW Stock Data
$18,581,874,872
177,467,581
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
